当前位置：药药网 / 药品研发 / 美国药品上市后承诺数据库
OBIZUR, Antihemophilic Factor (Recombinant), Porcine Sequence
药品名称
OBIZUR, Antihemophilic Factor (Recombinant), Porcine Sequence
承诺描述
To collect additional efficacy and safety data for OBIZUR in adults with acquired hemophilia A in the Treatment Registry study under Protocol 241302, “A Non-Interventional Study of Safety and Effectiveness of Recombinant Porcine Sequence FVIII (OBIZUR) in the Treatment of Bleeding Episodes for Patients with Acquired Hemophilia A.”
承诺状态描述
The final report due date has passed with no final report received
报告接收日期
2020/12/14 0:00:00